The SLC34A2 gene helps certain cells absorb phosphate, a mineral your body uses to build and maintain tissues. It is especially important in the lungs, where it helps keep the tiny air sacs clear. If this gene does not work properly, phosphate can build up with calcium and form very small deposits in the lungs. Over time, this may lead to cough, shortness of breath, and changes that show up on chest scans. Variants in the SLC34A2 gene are best known for causing pulmonary alveolar microlithiasis, a rare inherited lung condition.
What is a gene?
Genes are stretches of DNA that give your cells instructions to make molecules or to regulate processes in the body. Some genes carry the code for proteins, the parts of cells that do much of the work. Other genes mainly direct when certain processes happen, where they take place, and how strongly they run. Together, genes influence how the body develops and functions, and they can affect how you respond to food, stress, or medications. To explore this topic in more detail, you can learn more in the LearnHub.
Overview
SLC34A2Gene function
What if the gene works
The SLC34A2 gene helps certain cells absorb phosphate, a mineral your body uses to build bones, teeth, and cell membranes. It is especially active in the lungs and gut, where it supports normal cell function.
Risk
What if the gene does not work
Variants in the SLC34A2 gene most often cause pulmonary alveolar microlithiasis, with tiny calcium deposits building up in the lungs. Effects can range from no symptoms to cough, breathlessness, and reduced lung function, depending partly on variant severity.
Treatment
What does that mean for your treatment
No treatment specifically targets pathogenic variants in the SLC34A2 gene. Care is supportive, and lung transplantation can help in advanced pulmonary alveolar microlithiasis. Bisphosphonates have been studied, but they are not established guideline based therapy.
Conditions associated with SLC34A2
Gene function
What if the gene works
Your cells need phosphate for energy, cell membranes, and genetic material. The SLC34A2 gene helps certain lining cells, especially in the lungs and small intestine, bring phosphate in from nearby fluid. It does this by pairing phosphate movement with sodium, which makes transport more effective.
This gene helps lining cells take phosphate into the cell from the surface around them. That gives the body a steady supply of a mineral used in everyday cell work.
In the small intestine, its protein helps move phosphate from digested food into intestinal cells. This is an important part of how phosphate is absorbed in the small intestine.
In the lung air sacs, the transport protein helps remove phosphate from the thin fluid lining the surface. This supports the normal balance needed for surfactant, the soapy material that helps the air sacs stay open.
Its protein moves sodium and phosphate together across the cell surface. Using sodium as a partner makes phosphate transport more efficient and more controlled.
What is a variant?
A genetic variant is a minor change in a gene’s DNA sequence. These changes are common and help shape normal human diversity, including differences in appearance, metabolism, and the way the body responds to environmental influences. Many variants do not have any noticeable effect and are simply part of natural genetic variation. Sometimes, though, a variant changes how a gene works more significantly and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the SLC34A2 gene mainly reduce phosphate transport in lung lining cells. Some change the protein’s shape, stability, or movement to the cell surface, while more disruptive variants can stop the protein from being made or leave it with very little activity. This helps explain how variants influence the SLC34A2 gene's function: milder variants may keep some transport, while more severe variants are often linked to earlier or more extensive pulmonary alveolar microlithiasis.
How variants are linked to conditions
Pathogenic variants in the SLC34A2 gene cause pulmonary alveolar microlithiasis, a rare inherited lung condition in which tiny calcium deposits build up in the air sacs. In discussions of SLC34A2 gene variants and pulmonary alveolar microlithiasis, this is the main and best-established condition linked to the gene. People with this diagnosis may have no symptoms for years, or they may develop cough, shortness of breath, and lower exercise tolerance over time.
A variant is not necessarily a diagnosis
Gene variants are a routine part of human biology and are common across the general population. Most do not have a direct effect on health and instead represent natural human variation. For many genes, carrying a variant associated with a condition indicates a possible link rather than a definite diagnosis, especially when multiple genes and environmental factors also play a role. In some situations, however, a single well characterized variant in a specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
There is not yet broadly confirmed evidence on specific factors that increase or reduce risk related to the SLC34A2 gene. When someone inherits two nonworking copies, the chance of developing the related lung condition is mainly driven by the gene change itself. Avoiding smoking and other lung irritants may help protect overall lung health, but there is not enough evidence to say this lowers the genetic risk.
Inheritance of SLC34A2 variants
SLC34A2-related pulmonary alveolar microlithiasis is inherited in an autosomal recessive pattern. In how SLC34A2 variants are inherited, this means a person usually develops the condition only if they inherit two disease-causing variants in the SLC34A2 gene, one from each parent. Parents who each carry one variant are often unaffected carriers. With each pregnancy, two carrier parents have a 25% chance of having an affected child, a 50% chance of having a child who is a carrier, and a 25% chance of having a child without either familial variant.
What does my SLC34A2 result mean for my family?
For families affected by SLC34A2, the pattern is usually recessive, which means brothers and sisters may also have the condition or carry the same gene change even if they feel well. Parents are often healthy carriers. Children of someone with an SLC34A2-related condition will usually be carriers, and the chance of a child being affected depends on whether the other parent also carries a change in SLC34A2.
Genetic information
Genetic testing
How you find out about variants
To look for changes in the SLC34A2 gene, doctors use SLC34A2 genetic testing on a blood or saliva sample. A lab reads the gene’s DNA code and checks for variants linked with inherited lung calcification conditions. Results may show a disease-causing variant, no relevant variant, or an uncertain result.
When should I consider getting a genetic test?
Genetic testing for the SLC34A2 gene may be worth considering if lung scans show unusual calcium buildup in the air sacs or if this rare inherited lung condition runs in your family. A result can help confirm the cause and clarify whether close relatives may also carry the gene change.
A genetic result is only one part of your health story
A genetic result can be informative, but what it can tell you varies based on the condition and the type of variant involved. Over time, many other factors, including lifestyle, environment, age, and medical history, also shape how the body functions. For some conditions, especially those influenced by many genes, genetic information provides context rather than certainty and is most useful when considered together with other parts of care. In other situations, a genetic result may offer a clear answer. In areas like medication response, genetic results can also help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how your body responds to medicines. Small differences in genes can change how a drug is absorbed, broken down, moved through the body, or how strongly it acts at its target. This helps explain why the same medication works well for one person, has less effect for another, or causes more side effects in someone else.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in genes affect the way people respond to medicines. By studying links between genes and medications, it helps explain why the same treatment can work differently from one person to another. For many drugs, genes influence how the body handles a medicine or how strong its effects are. This information can support more personalized and informed treatment choices. More detail on this topic is available in the LearnHub.
Drugs influenced by the SLC34A2 gene
When should I seek medical advice?
There isn't yet a broadly confirmed role for this gene in predicting how medicines work, so concerns about side effects, new symptoms, or starting or changing treatment are best discussed with your doctor.
History
Pulmonary alveolar microlithiasis, the rare lung condition most closely linked to the SLC34A2 gene, was described in medical reports long before its genetic cause was known. In 2006, researchers identified disease causing variants in the SLC34A2 gene, giving families and clinicians a clear explanation for a condition that had seemed mysterious for decades. From these first observations, research expanded steadily, and case reports from different countries helped confirm the link. This discovery also clarified why the condition can appear in several members of the same family. Over time, descriptions became more precise as genetic testing allowed doctors to distinguish SLC34A2 related disease from other causes of lung calcification seen on scans.